Measles at the U.S.–Mexico border: The fragility of cross-border disease control

Measles, a highly contagious, vaccine preventable disease, has re-emerged as a significant public health threat in North America, driven by intense cross-border mobility and persistent gaps in vaccination coverage.The U.S.-Mexico border operates as a single epidemiologic space, with millions of people crossing the border for work, family, commerce, and health care, allowing a highly contagious virus such as measles to spread easily in communities where immunization levels fall below the 95% two-dose threshold.Recent surveillance highlights the scale of this resurgence: since 2025, the United States reported over 2,200 cases [1], while Mexico documented more than 9,000 cases and over 30 deaths [2]. Initial cases and early transmission in Texas:Public health authorities were alerted to the West Texas measles outbreak on January 24, 2025, after a hospital in Lubbock reported suspected measles in two children from Gaines County.The outbreak was announced on January 29 [3].Epidemiologic findings suggest broader community transmission, with reported illness clusters in unregistered private schools linked to Mennonite churches, including high absenteeism and temporary closures, though not independently verified.The primary case in Mexico was an unvaccinated Mennonite child from Cuauhtémoc, Chihuahua, who traveled to Seminole, Gaines County, Texas (Jan 20-24, 2025), coinciding with early cases there.Fever began January 29, with laboratory confirmation on March 20 [4], supporting likely exposure in Texas.This outbreak occurred in communities with less-than-optimal vaccination coverage.According to the Texas DSHS data for the 2024-2025 school year, MMR coverage in the county's three school districts was 77% among kindergarteners and 85% among seventh graders, with particularly low coverage in Loop Independent School District, where only 20% of kindergarteners were vaccinated [5].Meanwhile, in Mexico, the first dose of the MMR vaccine has only reached only 65% of children, while coverage for the second dose declined further to 50% [6].